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AbstrAct
Objective To determine the challenges in 
diagnosis, monitoring, support provision in the 
management of inflammatory bowel disease 
(IBD) patients and explore the adaptations of IBD 
services.
Methods Internet- based survey by invitation of 
IBD services across the UK from 8 to 14 April 
2020.
Results Respondents from 125 IBD services 
completed the survey. The number of whole- time 
equivalent gastroenterologists and IBD nurses 
providing elective outpatient care decreased 
significantly between baseline (median 4, IQR 
4–7.5 and median 3, IQR 2–4) to the point of 
survey (median 2, IQR 1–4.8 and median 2, IQR 
1–3) in the 6- week period following the onset 
of the COVID-19 pandemic (p<0.001 for both 
comparisons). Almost all (94%; 112/119) services 
reported an increase in IBD helpline activity. 
Face- to- face clinics were substituted for telephone 
consultation by 86% and video consultation by 
11% of services. A variation in the provision of 
laboratory faecal calprotectin testing was noted 
with 27% of services reporting no access to faecal 
calprotectin, and a further 32% reduced access. 
There was also significant curtailment of IBD- 
specific endoscopy and elective surgery.
Conclusions IBD services in the UK have 
implemented several adaptive strategies in order to 
continue to provide safe and high- quality care for 
patients. National Health Service organisations will 
need to consider the impact of these changes in 
current service delivery models and staffing levels 
when planning exit strategies for post- pandemic 
IBD care. Careful planning to manage the 
increased workload and to maintain IBD services is 
essential to ensure patient safety.
IntroductIon
The COVID-19 pandemic has significant 
implications for the diagnosis and manage-
ment of patients with gastrointestinal 
conditions including inflammatory bowel 
disease (IBD).1 Healthcare systems have 
had to adapt rapidly to maintain provision 
of core services and reduce unintended 
consequences from the necessary diver-
sion of resources to focus on the pandemic. 
summary box
What is already known on this topic
 ► COVID-19 pandemic is expected to pose 
a myriad of challenges to National Health 
Services.
 ► Essential services for inflammatory bowel 
disease (IBD) patients including outpatient 
care, advice lines, endoscopy and infusion 
units may be affected.
What this study adds
 ► This survey evaluates the challenges to 
IBD services during the pandemic and the 
adaptations to meet these challenges.
 ► There is significant reduction in staffing 
resources for the IBD team and significant 
increase in IBD advice line contact.
 ► Face- to- face consultations in outpatients, 
non- emergency endoscopies and elective 
IBD have been significantly curtailed.
 ► There is increased uptake of telemedicine, 
virtual multidisciplinary team meetings 
and non- invasive monitoring of patients.
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summary box
How might it impact on clinical practice in the 
foreseeable future
 ► There is urgent need to review models of care and 
staffing levels of IBD service in planning exit strategies in 
the post -pandemic period.
 ► Insights gained from the rapid adaptations by 
services during the peak of the pandemic may present 
opportunities for positive changes in IBD services.
The continued accumulation of cases positive for 
SARS- CoV-2 and the intervention from national govern-
ments to enforce strict social isolation (‘shielding’) and 
distancing have necessitated IBD services to dramati-
cally changing and restructuring the way they provide 
care for IBD patients.2 In addition, the rapid increase 
in COVID-19 hospitalisations along with restrictions 
in endoscopic and surgical facilities has resulted in the 
redeployment of clinicians and nurses to front- line 
services to care for these patients with resultant impact 
on the delivery of IBD care.3 In IBD, delays in diagnosis 
and therapy can have serious consequences including the 
need for emergency surgery.4
Patients are understandably concerned about the 
impact of their IBD and its treatment on their risk of 
severe COVID-19 disease. However, it is important 
that IBD patients continue to attend for inpatient, day 
case and outpatient hospital care for the management 
of active disease and complications and for thera-
pies such as intravenous biologics. Furthermore, given 
that immunosuppressive and biologic agents form the 
cornerstone of IBD management, concerns have been 
raised that patients with IBD may be more susceptible 
to SARS- CoV-2 infection and whether they may have 
poorer outcomes if infected with the virus.5 6 Although 
there are, as yet, no specific data quantifying additional 
risk, specialist societies and expert groups have recom-
mended heightened vigilance.7–9 In the UK, patients 
categorised as high risk have been recommended for 
isolation (‘shielding’) by UK Department of Health 
and Social Care,10 requiring individual IBD services to 
rapidly identify individuals in this group using hospital 
databases and registries.
The UK has a strong record of providing personalised 
multidisciplinary care for patients with IBD. Succes-
sive IBD audits have shown improvements in resource 
provision (including IBD nurses) and overall quality of 
care.11 12 More recently, a multidisciplinary stakeholder 
group has proposed key quality standards for IBD care 
in the UK.13 Maintaining high- quality care during the 
COVID-19 pandemic will remain a constantly evolving 
challenge. IBD clinicians and specialist nurses across the 
UK have formed an IBD COVID-19 working group to 
share expertise and promote a collaborative and co- ordi-
nated nationwide approach to meet the challenges posed 
by the pandemic. This has enabled the development 
of a UK consensus on management of IBD during the 
COVID-19 pandemic.8
The impact of the COVID-19 pandemic on provision 
of IBD care has not been previously evaluated. Most 
centres have rapidly and independently reconfigured 
their services guided by local management decisions 
based on varying service needs, redeployment of some 
of their staff and reconfiguration of available health-
care facilities. There has been limited opportunity or 
time to share experience of service reconfiguration 
to determine the impact across regions. We surveyed 
adult and paediatric gastroenterology services caring 
for IBD patients in the UK to assess the impact of 
COVID-19 on service delivery.
Methods
We developed an internet- based survey using Google 
Forms (Google, California, USA) to assess changes to 
IBD service provision in the COVID-19 period. This 
was circulated to IBD services throughout the UK 
through the membership of the UK IBD COVID-19 
working group and social media. The Royal College 
of Nursing (RCN) IBD specialist nurse network and 
the service leads of the services participating in the 
IBDUK self- assessment were also invited to participate. 
Furthermore, the survey was emailed to the member-
ship of the British Society of Paediatric Gastroenter-
ology, Hepatology and Nutrition (BSPGHAN). Survey 
participation was voluntary, and the option was given 
to provide the National Health Service (NHS) Trust 
identity and contact details with the option of being 
contacted for future surveys related to this subject. The 
survey was carried out between 8 and 14 April 2020, 
which corresponded to 1 month after the UK govern-
ment decision for lockdown. The survey (included in 
online supplementary appendix) covered the char-
acteristics and staffing resources of the services, the 
changes instituted in provision of IBD care in prepa-
ration for the COVID-19 pandemic and the impact of 
the pandemic on the provision of IBD services. Data 
were collected in Google Docs and then exported for 
analysis to Microsoft Excel (Microsoft, Washington, 
USA) and R V.3.6.0 (R Foundation for Statistical 
Computing, Vienna, Austria). Where more than one 
response was received from the same IBD service, 
the most recent response was used, though paediatric 
and adult services were counted as separate. Response 
frequencies were tabulated and expressed as percent-
ages of total responses; where there were incomplete 
responses to a question, this is reflected in the relevant 
denominator. Wilcoxon signed- rank tests were used to 
compare paired continuous variables. Fisher’s exact 
test was used to compare categorical data.
results
respondents
We received 147 responses representing 125 IBD 
services (England 106, Scotland 9, Wales 8 and 
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Figure 1 Likelihood of having less than the minimum number of 
required IBD healthcare professionals during the COVID-19 era. IBD, 
inflammatory bowel disease.
Northern Ireland 2) representing approximately 70% 
of the IBD services in the UK (paediatric services 19% 
of the total). Respondents included 65 (44%) adult 
gastroenterologists, 53 (36%) adult IBD nurses, 21 
(14%) paediatric gastroenterologists, 6 (4%) paedi-
atric IBD nurses and 1 IBD surgeon. Only the most 
recent response for each service was used. Fifty- seven 
per cent (71/124) were dedicated IBD services and 
43% (53/124) were general gastroenterology services 
providing IBD care. Fifty- seven per cent (70/123) 
of the services were based in a university teaching 
hospital, while 42% (52/123) were based in district 
general hospitals. All services who responded were 
based in public hospitals in the UK NHS.
Impact on work force
The overall number of whole- time equivalent (WTE) 
gastroenterologists and IBD nurses providing elective 
outpatient care decreased significantly between base-
line (median 4, IQR 4–7.5 and median 3, IQR 2–4) 
to the point of survey (median 2, IQR 1–4.8 and 
median 2, IQR 1–2) 6 weeks following the onset of 
the COVID-19 pandemic (p<0.001 for both compar-
isons). The proportion of services with more than 
three WTE gastroenterologists providing IBD care was 
81% (100/124) at baseline but fell to 34% (41/122) 
as a result of reconfiguration (p<0.001), with 8% 
(10/122) services having no dedicated IBD clinician in 
the COVID-19 era. Similarly, the number of services 
with more than one WTE IBD nurse fell from 81% 
(100/124) to 53% (63/118) (p<0.001). Eight per cent 
(9/118) of services stated that they had no provision 
for IBD nurse care. The main reasons given for the 
reduction in gastroenterologists and IBD nurses were 
redeployment (51% (64/125) and 40% (50/125), 
respectively), self- isolation due to COVID-19 symp-
toms (22% (27/125) and 17% (21/125)) and belonging 
to the shielding category (9% (11/125) and 14% 
(18/125)). The number of WTE nurses in adult IBD 
services dropped significantly from median 3 (IQR 
2–4) to 2 (IQR 1–3, p- value<0.001). In paediatric 
services, the median number of nurses was 2 (IQR 1–2) 
prior to COVID-19 and 1 (IQR 1–2) in the COVID-19 
era (p=0.24).
The median number of WTE gastroenterologists 
and IBD nurses required to provide IBD care for 
adult patients as self- assessed by our respondents were 
4.0 (IQR 2.4–5.0) and 3.0 (2.0–4.0), respectively. 
For paediatric services, the median number of WTE 
gastroenterologists and IBD nurses required to provide 
IBD care was reported as 2.0 (IQR 1.0–3.0) and 1.0 
(1.0–2.0), respectively. When asked about the possi-
bility of reduction in staff numbers below this required 
number as a result of COVID-19, 60% (72/119) of 
services thought this was certain or highly likely for 
gastroenterologists and 63% (70/123) for IBD nurses 
(figure 1).
Only 7% (9/125) of services reported that their 
IBD nurses could maintain their normal service. IBD 
specialist nursing support for inpatients was either 
not available for 26% (32/125) or curtailed by 31% 
(39/125) of the services. Similarly, nurse- led outpa-
tient clinics had been suspended by 27% (34/125) and 
reduced in a further 26% (33/125) of services.
Impact on Ibd service functions
Clinics
Significant changes were reported in the provision of 
outpatient IBD clinics. No service reported continuing 
normal activity with routine face- to- face appointments. 
Nine per cent of services reported running face- to- 
face clinics with reduced capacity, and 30% (38/125) 
reported complete cancellation of routine clinics. 
Face- to- face clinics were substituted with telephone 
consultation by 86% (108/125) and video consultation 
by 11% (14/125) of services; most services (13/14) 
using video were also using telephone consultations. 
The proportion of patients reviewed using telephone 
clinics was 100% in half of services (61/124) and above 
50% in a further 32% (40/124). In contrast, only 19% 
of services (23/123) reported having access to video 
consultation, with the majority (20/25) having access 
to video facilities reporting that they used them for less 
than a fifth of their consultations. We observed the use 
of patient apps in some services with 6% (7/123) and 
14% (17/123) of respondents, respectively, reporting 
current use or in set up.
Infusion services
Drug infusion services were relocated to a ‘safer 
area’ away from acute services by 50% (62/125). 
The majority, 62% (77/125), reported performing a 
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Figure 2 Change in inflammatory bowel disease advice line calls 
during the COVID-19 era.
Figure 3 Endoscopy provision during the COVID-19 pandemic. IBD, 
inflammatory bowel disease.
prescreening check list for COVID-19 before patients 
were invited to attend infusion services for treatment. 
Most services (77%, 96/125) reported maintaining 
infusion intervals with ‘enhanced provisions’ to reduce 
transmission but 11% (14/125) reported delaying 
treatment. Masks were reported as being used by staff 
in 61% (76/125) of services and by patients in 24% 
(30/125). Seven per cent (9/125) of services reported 
proactively switching their patients from intravenous 
to subcutaneous biologics. Sixty- two per cent (78/125) 
of services reported patient- initiated cancellation of 
at least some infusions; the most frequently reported 
proportion was approximately 10% of patients. 
Patient- reported reasons for cancellation included self- 
isolation due to COVID-19 symptoms and fears and 
concerns about therapies. Iron infusion services have 
been completely stopped by 16% (20/125) or curtailed 
by 45% (56/125) of services, respectively.
IBD advice line
The majority of services (94%; 112/119) report an 
increase in IBD advice line activity, with 80% (95/119) 
reporting a more than 50% increase and 34% (41/119) 
reporting a more than doubling of activity (figure 2).
Services are adapting to this increased demand using 
strategies such as an automated email (41%; 51/125), 
voice message response (45%; 56/125), more contact 
options (12%; 15/125) and additional staff overseeing/
providing IBD advice line services (10%; 13/125). 
Conversely, 29% (36/125) have reported a reduction 
in the number of staff providing advice line services.
Homecare services
Twenty- seven per cent (33/121) of services reported an 
inability to set up new homecare services for subcu-
taneous biologics and immune- modulatory therapy. In 
addition, 20% (25/122) also experienced disruption 
to the homecare delivery provision of therapies due 
to provider issues (28%; 3/125), blood monitoring 
issues (5%; 6/125), pharmacy issues (4%; 5/125) and a 
reduced number of nurses (5%; 6/125).
Endoscopy
In keeping with national guidance,14 endoscopy 
activity has been significantly curtailed for IBD patients 
with current provision only being available for defined 
high priority indications (figure 3). In 35% (44/125) 
of services, all IBD- related endoscopy activities have 
been cancelled.
Provision of IBD surgery
Potential elective surgery for IBD has been put on 
hold/withheld in all services surveyed. Indications for 
surgery that may be permitted include emergency small 
bowel resections in 74% of services (93/125), colec-
tomy for acute severe colitis in 72% (90/125), peri-
anal surgery in 42% (52/125) and colectomy for IBD 
dysplasia in 4% (5/125). In 10% (13/125) of services, 
all IBD surgery has been stopped.
IBD multidisciplinary team meetings (MDTs)
All IBD MDTs have been cancelled in 28% (34/122) 
of the services, while 40% (49/122) have converted 
them to virtual MDTs. Twenty- five per cent (30/122) 
of services are still running face- to- face MDTs, but 
with reduced capacity and/or social distancing. A 
small proportion either have put in place alternative 
arrangements (2%; 3/122) or never had MDTs to start 
with (5%; 6/122).
Laboratory services
Less frequent blood monitoring regimens for patients 
on immunomodulators have been adopted by 65% 
(79/121) of services, while 6% (7/121) have stopped 
all routine blood monitoring. The remainder of 
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Figure 4 Geographic variation around the UK in changes to 
provision of (A) faecal calprotectin, (B) endoscopy and (C) surgery. IBD, 
inflammatory bowel disease.
services (29%; 35/12) reported that they were contin-
uing normal monitoring arrangements.
There was significant variation in the provision of 
laboratory faecal calprotectin testing. A quarter of 
services (33/122) have no access to faecal calprotectin, 
while a further 32% (39/122) have reduced access. 
Point- of- care calprotectin has been introduced in 
5% (6/120) of services and scaled up in 2% (3/120); 
however, most services do not have access to point- of- 
care calprotectin analysis.
Flare services
Only half of the services (50%; 63/125) are providing 
access to face- to- face flare clinics. However, 77% 
(96/125) have access to blood tests in secondary care 
and 62% (77/125) to blood tests in primary care, 
while 12% (15/125) of services report no access at all 
to blood tests for flare. Fifty- eight per cent (73/125) 
had access to faecal calprotectin testing (home or labo-
ratory for flare managements). Endoscopy was only 
being used to assess suspected flares in outpatients 
with known IBD in 6% (8/125) of services.
Identification of high-risk patients
The UK Government introduced guidance on 21/22 
March 2020 to protect patients at risk of contracting 
COVID-19 based on emerging world data/medical 
advice. The concept of shielding was introduced, 
requesting patients in the highest risk category to with-
draw from society in their own homes for a period 
of 12 weeks. To support this endeavour, specialist 
societies including the British Society of Gastroenter-
ology developed guidance to risk stratify patients.8 
NHS trusts and health boards then had to iden-
tify the highest risk patients based on these criteria. 
At the time of the survey, 61% (76/125) of services 
reported having undertaken identification of high- risk 
patients who meet the criteria for shielding in their 
IBD cohorts and 76% (95/125) have already commu-
nicated with their highest risk patients. Furthermore, 
34% (42/125) of the services have communicated with 
their moderate risk patients. Seventy eight per cent of 
services (96/123) reported an intention to participate 
in the SECURE- IBD registry (https:// covidibd. org), 
which is recording the number of COVID cases in IBD 
patients; this includes 11% (14/123) who had already 
entered patients.
Geographic variation
Exploration of the variation in provision of services 
around the UK, including faecal calprotectin, endos-
copy and surgery, did not reveal any particular clus-
tering of loss of service into one region of the country 
(figure 4).
dIscussIon
The COVID-19 pandemic is having a pronounced 
impact on the lives of patients and healthcare 
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professionals (HCPs). IBD services in the UK mean-
while have also needed to adapt their priorities rapidly 
and modify current models of service to ensure delivery 
of a minimum standard of safe and effective care. This 
involved an urgent redesign of clinical services with 
clear communication among HCPs to develop an 
iterative model of care, responsive to the challenges 
posed by the unpredictable pandemic. The aim of this 
survey from the UK IBD COVID-19 working group 
was to explore, consider and disseminate examples of 
dynamic models of service provision.
Dramatic and significant reductions in staffing 
levels have inevitably impacted negatively on service 
provision and delivery. This has affected routine care 
for people with IBD including disease and treatment 
monitoring, clinical and endoscopic assessment, endo-
scopic surveillance, access to elective and semiurgent 
surgery and multidisciplinary team working. Despite 
this, most services have been able to adapt and have 
been innovative with service delivery and models of 
care with the aim of providing safe and effective care.
The unprecedented scale of this pandemic and 
uncertainties driven by the absence of ‘effective’ treat-
ment for COVID-9 has important implications for 
contingency planning with existing, evolving and aspi-
rational models of care delivery. Important elements 
such as staffing levels from redeployment, provision 
of ‘adequate’ monitoring, clear routes of access to 
specialist advice and urgent review, and the ability to 
start, continue and monitor effective therapies and 
outcomes will need careful consideration.
The high level of contact with IBD services by 
patients since the start of the pandemic demonstrates 
the ongoing requirement for suitably staffed advice 
lines and access to expert review, whether by tele-
phone, video or face- to- face clinics.
Wherever possible, arrangements should be made 
to facilitate some method of ongoing regular, sched-
uled MDT working, for discussion of complex or 
concerning cases needing consensus opinion. In 
addition, there will arguably be benefit to all team 
members of accessing peer and colleague support. 
Videoconferencing platforms provide a means to facil-
itate such discussions while ensuring staff can practise 
social distancing and, where possible and appropriate, 
work remotely. Where scheduled MDTs, either virtual 
or face to face, are no longer feasible due to changes in 
work schedules, other models of delivering care could 
be considered. Informal arrangements such as discus-
sion by email involving a suitable mix of specialist can 
provide short- term alternatives.
There has been rapid uptake by services of tele-
phone clinics, and some centres have instituted video 
consultations. Previous studies15–17 have assessed the 
impact of telemedicine systems in IBD assessing feasi-
bility, patient acceptance, effectiveness and impact 
on healthcare utilisation. However, there are several 
potential barriers18 and further adoption and upscaling 
of teleconsultation tools are urgently warranted. There 
is an ongoing international survey of telemedicine in 
IBD in the COVID-19 era organised by the Interna-
tional Organisation for the Study of IBD.
IBD patients appear to be receptive to the idea of 
non- face- to- face review where appropriate, with 
low levels of non- attendance reported to telephone 
and virtual appointments.19 Reviewing patients also 
provides an opportunity to check their understanding 
of the ongoing pandemic, the impact it has on them as 
individuals and any effect it may have on their treat-
ment. This should promote adherence to therapy, as 
well as facilitating early management of disease flares. 
Future surveys should assess patients’ preferences 
for telemedicine as we plan services following the 
COVID-19 pandemic.
IBD endoscopy practice during the ongoing 
COVID-19 pandemic appears to be broadly in line with 
national and international consensus.14 20–22 Endos-
copy services have been rationalised to provide the 
most urgent information for the safe care of patients 
such as in the management of acute severe colitis. Simi-
larly, elective surgery has been stopped with a focus 
on emergency surgery for acute severe colitis, emer-
gency small bowel resection and drainage for perianal 
sepsis. There are concerns about the potential impact 
of delaying elective endoscopies and operations in 
patients with IBD. Services will need to make plans 
for appropriate prioritisation of delayed procedures 
including those needing diagnosis of new IBD or/and 
those needing surveillance to ensure safety in the post- 
pandemic era.22
Currently, the UK consensus guidelines do not 
recommend cessation of therapies such as biologics 
and immunomodulators in IBD patients who currently 
do not have COVID-19.8 In those who stop therapies 
during illness with SARS- CoV2 or following a posi-
tive test, current guidelines recommend that biologics 
and immunomodulators are recommenced soon after 
cessation of symptoms.8 9 The IBD services surveyed 
here appear to have taken prompt action to ensure 
continuity of treatments in infusion units, but logistical 
challenges with location and delivery of treatments 
remain; a significant proportion of services reported 
difficulties in delivery of infusions. This may worsen 
as the pandemic progresses over time due to patient 
factors such as shielding, isolation due to contact and 
fears about safety as well as staffing- related challenges 
depending on the duration of the pandemic or indeed 
new peaks in the pandemic. Adoption of subcutaneous 
therapies among patients starting biologic therapy 
may reduce the pressures on infusion units and 
reduce patient footfall in the hospital site. However, a 
concerning number are reporting difficulties in starting 
new home care treatments and also in the delivery of 
ongoing treatments, which needs addressing urgently.
IBD advice lines are an immensely valuable resource 
for patients with IBD,23 and this is more so when 
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elective activity has been curtailed as evidenced in our 
survey. The marked increase in the number of patients 
accessing IBD advice lines, coupled with a reduction in 
the number of staff in more than a quarter of services, 
is likely to impact provision of prompt support and 
advice to patients, who are understandably concerned 
about the potential impact of IBD and their medica-
tions during the COVID-19 pandemic. Services have 
attempted to provide more online support, but the 
unprecedented increase in number of contacts may 
prove overwhelming. It is likely that requests for 
advice regarding social distancing and shielding will 
reduce, but the number of patients contacting IBD 
advice lines for flare management may rise as routine 
outpatient clinics have been stopped or have limited 
access in many centres.
Non- invasive assessment and monitoring of IBD 
are critical during the COVID-19 pandemic. Hence, 
it is unfortunate that several services report cessation 
of faecal calprotectin services, mainly due to concerns 
regarding risks to laboratory staff, although faeco- 
oral transmission is not confirmed yet. SARS- CoV-224 
has been detected in faeces even in asymptomatic 
patients with COVID-19; however, it is not clear if 
this represents live virus. One option for such services 
is to initiate and upscale the use of point- of- care faecal 
calprotectin testing.25 A major concern highlighted by 
this survey is the significant reduction in both clini-
cians and specialist nurses available to care for IBD 
patients. More than 50% of the respondents felt that 
the services would remain understaffed and unable 
to meet the needs of IBD patients. Redeployment to 
front- line COVID-19 duties appears to be the main 
factor, and this may need addressing at unit level with 
measures such as creation of a designated core team 
of clinicians and specialist nurses to deliver IBD care, 
as adopted by centres in Italy.26 We should also ensure 
that, where the local COVID-19 situation permits, 
IBD specialist nurses and doctors are able to resume 
their responsibilities in IBD care.
Our survey has some limitations. We could not 
capture responses of all IBD services in the UK. We 
were, however, able to reach out to approximately 
70% of UK IBD services who registered for the recent 
unit and patient assessment of services under IBDUK 
(https:// ibduk. org/ services- map). The epidemic is at 
different stages across the UK, but as can be seen in 
figure 4, we have good geographic coverage of the 
country. It is possible that some of the most under- 
resourced IBD services may also have been less likely 
to have someone available to complete the survey. 
Finally, the rapidly evolving nature of data and 
guidelines relating to COVID-19 in IBD make future 
assessment of service provision important to ensure 
equitable access to high- quality IBD care across the 
country.
conclusIons
In this survey, we provide a comparative reference 
to support consistency of care across the UK during 
a difficult time and to offer a template to centres in 
other countries, which have yet to undergo such alter-
ations. It is our hope that this will allow services to 
make suitable arrangements to maintain high- quality 
uninterrupted care for patients with IBD. The ongoing 
COVID-19 pandemic has and may continue to pose 
myriad challenges to healthcare systems across the 
globe. IBD services in the UK and other countries will 
face unique challenges both during the peak and post- 
peak pandemic period with respect to responsive and 
responsible adaptation of service delivery. These are 
unprecedented and challenging times. Yet, even grim 
challenges present opportunities not in the least with 
insights gleaned from rapid adaptation of models of 
service delivery some of which are likely to be also 
suitable in a post- COVID-19 world. Indeed, there may 
be opportunities for positive changes in IBD services 
resulting from this difficult time.
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